Track the questions your buyers ask and see where competitors are winning attention.
02
Act on what matters
Strengthen your content, technical foundations and presence on the sites AI answers draw on.
03
Improve month by month
Review what changed and agree the next priorities around your commercial goals.
Vantage is independent of Tilio’s client work. No company can pay to be included or moved, and a listing does not mean a company is a Tilio client.
Vantage | Pharmaceuticals AI visibility ranking, UK | Tilio
Pharmaceuticals
AstraZeneca leads the UK ranking for pharmaceuticals, scoring 1.9% on the AI visibility index in the scan of 27 Oct 2026.
AI visibility is the share of AI answers that mention a brand. Compare brand rankings and weekly changes across ChatGPT, Google AI Overviews and Google AI Mode. Measured and published 27 Oct 2026. The same 180 buying questions went to ChatGPT, Google AI Overviews and Google AI Mode, and each brand's score is the share of the 533 answers that named it.
ChatGPT
Google AI Overviews
Ranking
13 companies
Category average 0.6%
Companies ranked by visibility. Change is in percentage points against the previous published scan.
1.9%–No change shown: First published reading, so there is nothing to compare against yet.
Named in 10 of 533 eligible answers, 0.8 pp ahead of GSK.
Companies measuredEvery measured company was named in at least one eligible answer this week.
13
Questions askedQuestion set universe-4052b48d578c. The same fixed set, sent to every engine at the start of the scan. Questions never name a company.
180
Eligible answersAnswers the engines actually produced. 100% of planned attempts completed. Searches with no AI answer are left out of the denominator.
533
Category averageThe mean visibility of every company measured in the industry this week.
0.6%
A mention is not a recommendation or a quality rating, and a listing does not mean the company is a Tilio client.
20
Procurement and supplier relationships14
Industry structure and medicine types16
Over-the-counter medicines and pharmacy8
Prescription access and pathways13
Generics and biosimilars11
Medicine discovery and development4
Careers and skills6
Veterinary medicines16
Business models and investment6
Clinical research and trials5
Sustainability and environmental impact7
Safety and pharmacovigilance7
Regulation and marketing authorisation8
Supply chains and shortages13
NHS access, appraisal and reimbursement10
Pricing and private access1
Manufacturing and quality7
Specialist and advanced medicines8
Questions are the accepted, unbranded buyer questions of a Tilio Prompt Universe research run, modelled from an approved coverage plan and reviewed by Tilio. Where the run asked a question in more than one wording, every wording counts towards that question. Each run of the same questions is one scan. No question carries a measured search volume.
Question set universe-4052b48d578c, 180 questions, each asked once per engine per scan. Questions never name a company.
See all 180 questions
Safe use, adherence and monitoring · 20
What routine checks or tests might be needed while I continue my prescribed medicine, and how can I confirm these are covered in my clinical review?
I am experiencing side effects from my existing prescription. What should I tell my prescriber at a clinical review before making any change?
How can I judge whether my current prescribed medicine is still providing enough benefit to justify continuing it, and what should I raise at a clinical review?
After a recent change to my dose or instructions, how should I check at a clinical review whether my current prescribed medicine remains safe and beneficial to continue?
As a carer, how can I help someone prepare for a clinical review of their existing medicine if they are unsure it is still helping, without changing it beforehand?
I sometimes struggle to take my existing prescription consistently. What support can I ask for at a clinical review before deciding whether this treatment is still right for me?
My symptoms are well controlled on my existing prescription. How can a clinical review weigh its ongoing benefits and risks before I decide whether to continue?
How often should a long-term medicine be reviewed to check that it remains safe and worthwhile, and who should arrange the clinical review?
I sometimes can’t remember whether I’ve taken my medicine. How can I keep track safely?
My eyesight makes medicine labels difficult to read. What support can help me check the instructions safely?
I’m unsure what the instructions mean when some of my medicines need to be taken with food. How can I check?
I’m not sure where to store a medicine or how to tell if it has expired. Where can I check the safe storage instructions?
I help an older relative with their medicines. How can I support them to take them safely while respecting their independence?
I struggle to swallow my tablets. Who can advise me on what to do safely?
I feel unwell after taking a medicine. What should I record, and who should I contact for advice?
If one brand has different storage or handling instructions from another, what should I confirm with my pharmacist about safe use, missed doses and monitoring before changing?
I am weighing two branded treatments and may use NHS-funded or private care. What should I ask my clinician about follow-up, access and continuity of monitoring in each setting?
When comparing two branded options for my condition, what should I ask my prescriber about likely side effects, monitoring and how practical each dosing routine would be for me?
I take several medicines. Which interaction checks and monitoring questions should I raise with my prescriber when comparing two branded treatment options?
If two brands have the same active ingredient, what formulation and administration differences should I check with a pharmacist before switching from my current prescription?
Procurement and supplier relationships · 14
If supplier performance has improved after a corrective action plan, what should commissioners look for to decide whether that improvement is durable enough to renew the supply arrangement?
How should we assess whether repeated late deliveries are caused by our supplier or broader market shortages before deciding whether to renew or change the arrangement?
Our supplier offers a low price but has had quality complaints and slow issue resolution. How should we weigh those service concerns against the cost and continuity risks of switching at contract renewal?
Which delivery, fulfilment, shortage and response-time measures should commissioners use to judge whether the current supplier is still providing value for money at renewal?
How can we calculate the full transition cost of changing medicine suppliers, including stock cover, implementation and potential disruption, to compare it fairly with renewing?
Under UK procurement rules, when is renewing or extending an existing medicine supply contract preferable to retendering while maintaining value for money and continuity?
For an essential medicine, how should a procurement team compare two suppliers’ contingency plans and capacity to maintain supply if production is disrupted?
Which commercial factors should we use to compare medicine suppliers’ overall value, including payment terms, rebates, service levels and avoidable wastage?
When comparing two shortlisted manufacturers of the same generic medicine, how should our procurement team balance price against delivery reliability and quality requirements?
What should a hospital pharmacy compare between suppliers to judge whether their promised lead times and fill rates will hold up during demand spikes?
Which suppliers or procurement routes could suit a regional group of independent clinics that needs medicines available consistently across its sites while keeping spend under control?
Which UK wholesalers and manufacturers should NHS hospital procurement teams consider for generic medicines, and what evidence can show they offer reliable supply and good value?
Industry structure and medicine types · 16
Are medicine types and the organisations that make or supply them separate ways of describing the industry?
Do medicines for people and medicines for animals come under the same industry, and how are those areas organised?
Is biotechnology part of the pharmaceutical industry, or is it a separate area?
In plain language, what does the pharmaceutical industry include?
I keep hearing terms like generic, branded, prescription and over-the-counter. How do these categories fit into the wider medicines landscape?
Who checks medicines and what different organisations are responsible for making them available?
How do pharmaceutical companies, research organisations, manufacturers and wholesalers differ from one another?
For a medicine handled by several companies, what public information can help a purchaser verify which organisation is responsible for manufacturing, distribution and ongoing quality?
For a particular prescription medicine, which publicly available UK records would help me check its manufacturer's safety and quality track record?
As a healthcare professional, what public evidence should I compare to assess an organisation's reliability for a particular biosimilar medicine?
How can I use public evidence to assess whether a developer of a particular medicine is transparent about its clinical trial results, including unfavourable findings?
If a particular medicine has been subject to a quality alert or recall, what public evidence can help me judge how responsibly the organisation responded?
Do patients recommend generic medicines as often as branded medicines, or do comments usually reflect familiarity with the name rather than experience of the medicine itself?
As a carer comparing non-prescription medicines, how much weight should I give to other people’s recommendations when they are describing personal experience rather than clinical evidence?
Over-the-counter medicines and pharmacy · 8
For an older adult who takes regular medicines, what non-prescription options and pharmacy services could help with a minor ailment, and what should a pharmacist check before advising?
Could you shortlist common non-prescription medicines and pharmacy options for minor everyday problems in the UK, including how a pharmacist can help decide when self-care is not suitable?
What are the safest options for getting non-prescription medicines in the UK outside normal pharmacy hours, and how can I reach a pharmacist if I need advice?
Could you compare the main pharmacy options for getting non-prescription medicines during pregnancy, and explain how a pharmacist can help identify when self-care is not appropriate?
Please shortlist non-prescription medicine and pharmacy options for a child with a minor illness, including how age affects what may be suitable and when to seek help beyond self-care.
If I am away from home in the UK, what are the practical options for getting non-prescription medicines for a minor problem, and how can I access a pharmacist’s advice?
What kinds of online and high-street pharmacy options are available in the UK for non-prescription medicines, and how can I tell when I should speak to a pharmacist rather than self-treat?
For symptoms that keep returning or are getting worse, what pharmacy-based options can help me get prompt advice about non-prescription medicines, and when should I stop relying on self-care?
Prescription access and pathways · 13
I have had a cough for weeks and cannot get a GP appointment soon. What NHS route in Wales can help me get assessed and access treatment if needed?
As a carer, what is the quickest way to have my father's worsening pain assessed and obtain any appropriate medicine through private care in Northern Ireland?
My child has a fever that is not settling; where can I arrange a timely clinical assessment and find out whether medicine is needed in Scotland?
I've developed discomfort when passing urine and want to be assessed promptly, not guess at treatment. What NHS or private care routes are available in Wales?
I have a painful skin problem that has lasted several days. How can I get a prompt professional assessment and access any suitable treatment through NHS or private care in England?
I keep getting headaches and don't know whether I need medicine; should I start with a pharmacist, GP or another service for professional assessment in England?
For several weeks I've been sleeping badly and it's affecting my day. How can I get a timely professional review and find out whether treatment is appropriate via the NHS in Scotland?
I've had recurring stomach discomfort and would like a clinician to decide whether treatment is needed. What are my quickest options for an NHS or private appointment?
I’m moving from Scotland to Wales and need to keep getting an existing prescription-only medicine. What NHS or private care pathways could help avoid an interruption during the move?
My repeat prescription for a prescription-only medicine is due, but I can’t get an appointment with my usual prescriber for several weeks. What NHS or private care routes could help me avoid a gap in treatment?
As a carer, what NHS or private care options could help someone who is housebound receive their existing prescription-only medicine on time?
I may run out of my prescription-only medicine over a weekend or bank holiday. What NHS or private care routes could help me get advice and, if suitable, a timely supply?
Generics and biosimilars · 11
What should I check with my prescriber or pharmacist before switching my prescription from a reference medicine to a generic?
How do the approval and evidence standards for a prescribed biosimilar compare with those for its reference biologic, and what does that mean for confidence in treatment?
For someone prescribed a biologic, what clinical evidence and practical factors should a healthcare professional compare before switching from the reference biologic to a biosimilar?
For a prescribed generic and its reference medicine, what differences in inactive ingredients or tablet appearance could matter to a patient?
When comparing a prescribed generic medicine with its reference brand, what evidence shows whether they are expected to work similarly?
What evidence supports switching someone who is stable on a reference biological medicine to a biosimilar, rather than continuing their current treatment?
When a biosimilar is approved for more than one condition, what evidence supports comparing it with the reference medicine in each condition?
If specialist prescribing or monitoring is required, how should I compare the administration and monitoring requirements of a biosimilar with its reference medicine?
How do the safety findings and risk of an immune response compare between a biosimilar and its reference medicine?
How strong is the evidence that a biosimilar performs as well as its reference medicine, and why is a biosimilar not simply a generic version?
What evidence should NHS commissioners compare to judge whether a biosimilar and its reference medicine offer comparable clinical outcomes across the patients treated?
Medicine discovery and development · 4
Why do promising medicine candidates sometimes produce preclinical results that other laboratories cannot reproduce?
What evidence gaps commonly explain why strong preclinical findings do not translate into early clinical studies?
Why can it be so difficult to draw reliable conclusions from early clinical studies with small numbers of participants?
At what development stage do gaps in safety or efficacy evidence tend to cause the longest delays, and why?
Careers and skills · 6
What commercial roles are available in the UK pharmaceutical industry, from medical sales and market access to marketing, and what backgrounds tend to fit each?
Which pharmaceutical roles might suit someone changing careers from healthcare, and what additional training or experience could help them move into research, safety or regulatory work?
Which pharmaceutical manufacturing and quality roles offer realistic entry routes for someone with a science or engineering background?
I have project coordination and data skills but no pharmaceutical experience. Which UK industry support roles could I consider, and how could I get started?
What entry routes should UK students compare for careers in pharmaceutical research, manufacturing, regulation, medicine safety and commercial teams, including apprenticeships and graduate programmes?
What research roles in the UK pharmaceutical industry could suit a biology graduate, and what qualifications or experience do they usually require?
Veterinary medicines · 16
For a medicine intended for food-producing animals, where can I check the withdrawal periods, permitted species and records required for responsible use?
If an animal has a suspected adverse reaction to a veterinary medicine, what is the UK reporting route and what information is useful to provide?
What should I check on the packaging and product information to confirm a veterinary medicine is genuine and properly labelled for the UK market?
How can I check that an online seller is legally allowed to supply a veterinary medicine in the UK before placing an order?
When can a veterinary surgeon use the prescribing cascade instead of a medicine authorised for that species, and what additional safeguards apply to food-producing animals?
Before settling on a veterinary medicine, how can I confirm it has a current UK authorisation and that the authorised species and indication match its product information?
How do UK rules distinguish veterinary medicines that can be supplied without a prescription from prescription-only medicines, and who is allowed to supply each?
What storage, expiry and handling checks should I make when accepting a veterinary medicine from a supplier, and where should I find the product-specific instructions?
What treatment options might a vet shortlist for footrot in food-producing sheep, and what should a farmer check before treating the flock?
For mites in food-producing laying hens, what medicine options can a vet advise on, and how do egg withdrawal requirements affect the choice?
For a dog with fleas, what are the main veterinary medicine options, and how can a vet help an owner choose one that is safe for dogs?
If my dog has a suspected ear infection, what medicine types might a vet shortlist, and how would they decide between ear drops and other treatment?
For mastitis in food-producing cattle, what medicines might a vet consider, and how should milk withdrawal periods influence the choice?
Business models and investment · 6
How should I compare a preclinical platform biotechnology company with a clinical-stage single-asset drug developer, weighing scientific promise against development risk and commercial performance?
Which business model looks more commercially resilient in the UK: developing specialist medicines that depend on NHS funding or building a portfolio of non-prescription consumer health products?
For a pharmaceutical investor, how do rare disease medicines compare with high-volume chronic disease treatments in risk-adjusted commercial potential, given uncertainty about demand and market uptake?
As an investment, how does a contract development and manufacturing business compare with a company that owns its medicine assets, particularly in revenue visibility and downside risk?
For a UK investor, how should I compare the commercial prospects of a novel-medicine developer with those of a generic medicines manufacturer when the scientific outcome is uncertain?
Should a UK pharmaceutical start-up license its medicine candidate to a larger company or fund development and commercialisation itself, given its limited capital and tolerance for risk?
Clinical research and trials · 5
What practical questions should I ask about a UK trial's visits, travel, expenses and support for carers before deciding whether to take part?
Before considering a UK clinical trial, how can I find out who monitors participant safety and how possible harms are reported and acted on?
What should a clinical trial's consent materials explain about eligibility criteria, foreseeable risks and the right to withdraw before someone agrees?
As a healthcare professional, what should I review in a UK trial's protocol, outcome measures and reporting plan to judge whether its evidence will be reliable?
Where can a carer find a shortlist of UK research trials seeking volunteers with a dementia diagnosis, and how can families express interest?
Sustainability and environmental impact · 7
Which approaches can reduce emissions from pharmaceutical transport, including temperature-controlled distribution, without undermining medicine quality, safety or reliable supply or breaching regulatory and quality requirements?
Which manufacturing approaches can reduce pharmaceutical water use and wastewater impacts while satisfying regulatory and quality requirements and protecting medicine quality, safety and continuity of supply?
What options can pharmaceutical businesses use to prevent production waste and improve reuse or recycling across the supply chain, while meeting regulatory and quality requirements and avoiding risks to medicine quality, safety and supply reliability?
Which procurement or supplier-assessment approaches can healthcare providers and policymakers use to favour lower-impact pharmaceutical manufacturing and supply chains, while upholding regulatory and quality requirements and ensuring medicines remain safe and reliably supplied?
What are the best options for reducing packaging materials and their environmental footprint across pharmaceutical manufacturing and supply chains, while preserving medicine quality, patient safety and reliable supply within regulatory and quality requirements?
Which options for decarbonising pharmaceutical manufacturing are most practical while meeting regulatory and quality requirements and maintaining medicine quality, safety and reliable supply?
Please shortlist options for cutting solvent use and emissions during medicine manufacturing, including the trade-offs for product quality, safety and reliable supply under regulatory and quality requirements.
Safety and pharmacovigilance · 7
As a healthcare professional, how should I submit a suspected adverse reaction through the UK reporting route, and how are reports considered alongside other safety evidence?
Can I make a UK report about a suspected side effect if I don’t know all the details, and does a report alone confirm that the medicine was responsible?
I’m caring for someone who may have had a reaction to a medicine. How can I report it through the UK reporting route, and can one report show that the medicine caused it?
Is it still worth reporting a suspected side effect through the UK reporting route if it is already listed for the medicine, and what does the report add without proving causation?
I'm caring for someone who's suddenly confused after taking their medicine. Should I seek emergency help now or contact their doctor or pharmacist?
Could a new medicine be causing dizziness alongside my other tablets, and what should I tell a pharmacist or doctor so they can check for interactions?
I may have taken an extra dose by mistake. What should I do now, and should I contact a pharmacist or seek urgent medical help?
Regulation and marketing authorisation · 8
Once a medicine is authorised in the UK, how are new side effects monitored, and what can regulators do if a safety signal appears?
I’m considering a UK-authorised prescription-only medicine. What does its marketing authorisation actually tell me about its quality, safety and effectiveness?
What does UK authorisation establish for a non-prescription medicine, and how is that different from the rules for buying it without a prescription?
Can a medicine authorised in the UK still be used off-label, and how does that differ from what the regulator has approved?
For a pharmaceutical company, what regulatory checks on manufacturing and ongoing quality sit alongside a medicine’s UK marketing authorisation?
Where can I check whether a medicine is currently authorised in the UK and which uses its authorisation covers?
If a medicine has UK marketing authorisation, does that guarantee an NHS-funded option or mean a clinician must prescribe it for a particular patient?
Does UK marketing authorisation cover use in every age group and for every condition, or only the groups and uses assessed in the product information?
Supply chains and shortages · 13
How can a hospital team choose between redistributing stock, prioritising patients by clinical need and using an approved alternative when a medicine shortage becomes severe, with the relevant specialists involved?
For a prescribed medicine with limited stock and unpredictable deliveries, how can community pharmacies and prescribers coordinate repeat prescriptions, staggered dispensing and follow-up to reduce gaps in treatment?
When a shortage affects only some strengths or formulations of a prescribed medicine, what options can the prescriber and dispensing pharmacist assess to maintain treatment safely, and what should patients avoid doing themselves?
If supplies of a medicine that requires specialist prescribing or monitoring are limited, what options should a patient discuss with their specialist, including a temporary switch or a different care setting?
If usual wholesalers cannot supply a prescribed medicine for several weeks, what approved supply routes or alternative products can a pharmacist explore with the prescriber before treatment is interrupted?
In the UK, do the steps for an unavailable prescription-only medicine differ between England, Scotland, Wales and Northern Ireland, and where should patients check?
A patient is ready to leave hospital but their prescribed medicine is unavailable. Who should coordinate a safe supply plan before discharge?
My repeat prescription for a prescribed medicine is delayed and I only have a few doses left. Who should I contact to prevent a gap in supply?
My GP and pharmacy each say the other needs to resolve a shortage of my prescribed medicine. How can I get the right people to coordinate its supply?
I’m due for hospital treatment involving a prescribed medicine, but the clinic says it has not arrived. Who can help sort out continuity before my appointment?
I’m a pharmacist and a wholesaler cannot supply a prescription-only medicine I dispense. Who should I contact to escalate the shortage and help maintain patients’ treatment?
When specialist handling is needed, what might cause medicines to arrive late or be rejected in the UK supply chain, and how could that disrupt supply without causing obvious damage?
NHS access, appraisal and reimbursement · 10
How much weight do NHS appraisers give to real-world outcomes and patient experience when clinical trial evidence is limited, and how might that affect access?
For a medicine assessed through a specialist or rare-disease pathway, what decision details confirm whether funding covers starting treatment, ongoing use and monitoring?
When an NHS appraisal recommends a medicine only for a defined patient group, how can patients and clinicians check whether someone meets the eligibility criteria?
My doctor thinks a medicine may help, but says it might not be suitable for me. How can that affect whether I can get it on the NHS in England?
If the NHS has agreed to fund a medicine, why can it still take months before a local clinic offers it?
How can we check whether the NHS has appraised and funded a medicine for a rare disease in Scotland, and what access route might remain if it has not been recommended?
After a rare-disease medicine is approved for NHS funding in Scotland, where can a carer find practical guidance on referral and the next steps to access treatment?
We are weighing private care against waiting for NHS access to a rare-disease medicine in England. What costs and continuity-of-care points should we check before deciding?
In England, what routes can a family explore if a medicine for a rare disease is not routinely available through the NHS, including specialist services, appraisal and funding?
My specialist recommends a medicine for a rare disease, but our local hospital cannot provide it. In Wales, could a specialist centre provide the treatment, and who would arrange prescribing and monitoring?
Pricing and private access · 1
How can I estimate the first-year cost of a medicine through private care, separating the medicine, initial and follow-up consultations, dispensing and monitoring from ongoing costs?
Manufacturing and quality · 7
For sterile injectable medicines supplied in the UK, what evidence should a procurement team review to verify that a manufacturer meets required good manufacturing practice standards?
What should a quality agreement require a manufacturer and supplier to do when there is a deviation, a process change or a product recall?
When an out-of-specification result occurs, what investigation and corrective-action records should a quality auditor examine to judge whether it was handled adequately?
What checks help a hospital procurement team confirm that each batch has been properly tested and released before supply?
How much reassurance should a current MHRA good manufacturing practice inspection provide about a manufacturer’s ongoing compliance, and what does it not establish about a medicine?
How can a manufacturer demonstrate that active ingredients and finished packs are traceable through its supply chain?
For a biologic medicine, how should batch-to-batch consistency be monitored and documented, and what records can a buyer reasonably ask to see?
Specialist and advanced medicines · 8
Which cell and gene therapies and UK access routes are worth considering for NHS-funded or private treatment, and what specialist centres, prescribing and follow-up do they require?
How do NHS access routes for hospital-only specialist medicines differ across England, Scotland, Wales and Northern Ireland, and what private options might patients ask about?
What access routes and specialist teams are available for children who need an advanced medicine, including prescribing, administration and ongoing monitoring?
I’m looking for UK services that can assess eligibility and arrange access to an advanced medicine through NHS or private care. What types of service should I compare?
For a rare disease with several specialist treatment options, which medicines may be accessed through the NHS, and what eligibility criteria and specialist prescribing requirements apply?
What are the main specialist medicine options for conditions requiring hospital infusions, and what administration and ongoing monitoring services do they involve?
For an advanced medicine that needs refrigerated handling, which NHS or private providers can arrange specialist prescribing, administration and monitoring, and what cold-chain services should I check?
Which specialist medicines may be considered when standard treatments have not worked, and what specialist assessment and follow-up services are available?
What each engine contributed
Answers collected per engine in this scan
Engine
Eligible answers
No AI answer
Completed
ChatGPT
180
–None
100%
Google AI Overviews
173
4%
100%
Google AI Mode
180
–None
100%
“No AI answer” is a completed search where the engine showed nothing to analyse, most often a Google search with no AI Overview. Those searches are reported here and left out of the denominator. “Completed” is the share of planned attempts that finished; a scan under the publication threshold is held rather than published.
For a multi-site independent hospital group, what are the advantages and disadvantages of buying medicines directly from manufacturers rather than through wholesalers, particularly for supply reliability and overall cost?
What tendering or framework routes can NHS and private healthcare buyers use to identify reliable medicine suppliers and compare value while meeting procurement requirements?
Do healthcare professionals recommend certain medicine formulations because they are easier for patients to use, and how is that practical feedback different from evidence of effectiveness?
Where do patients and carers in the UK typically share recommendations about medicines, and how can I tell whether those accounts describe genuine experience rather than clinical proof?
A hospital specialist has recommended a prescription-only medicine that I’m not yet receiving. What NHS or private care pathways could arrange a timely review and supply if it’s appropriate for me?
What pain-relief medicines may be suitable for a horse after a minor injury, and what checks should an equine vet make before recommending one?
Which worming medicines are commonly considered for cats, and what should I ask my vet about when choosing the right option?
What treatment medicines should I discuss with an exotic-animal vet for a skin infection in a pet rabbit, given that some medicines used in other species may be unsuitable?
How might storage conditions that differ from a medicine’s requirements at a wholesaler affect its quality by the time a pharmacy receives it?
